Myo-Inositol as an Adjuvant to Letrozole for Infertility in PolyCystic Ovary Syndrome (MALI-PCOS): a Randomized Pilot Trial

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This will be a prospective, double-blind randomized clinical trial of letrozole and placebo versus letrozole and inositols for up to 5 treatment cycles of ovulation induction or until pregnancy is achieved. All participants and members of the research team will be blinded to the treatment arms. Placebo and inositol supplement will be packaged to appear the same, tested, and packaged by a commercial supply company. The inositols will be a 40:1 blend of myo-inositol and D-chiro inositol.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 36
Healthy Volunteers: f
View:

• Female patient age 18-36

• Desire for pregnancy

• Diagnosis of oligo- or anovulation secondary to polycystic ovary syndrome -All subjects must have ovulatory dysfunction and at least one of the remaining two criteria:hyperandrogenism or polycystic ovarian morphology on ultrasound

• At least one patent fallopian tube

• Normal uterine cavity

• Male partner with sperm concentration of at least 14 million/mL in at least one ejaculate.

Locations
United States
Oklahoma
OUHSC Reproductive Medicine Clinic
RECRUITING
Oklahoma City
Contact Information
Primary
Christy Zornes, MHR
christy-zornes@ouhsc.edu
4052718001
Backup
Kyra Woods, BA
kyra-woods@ouhsc.edu
4052718001
Time Frame
Start Date: 2020-12-19
Estimated Completion Date: 2025-12
Participants
Target number of participants: 168
Treatments
Placebo_comparator: Control Arm
This group will receive placebo powder twice daily.
Active_comparator: Inositol Arm
This group will receive myo-inositol (2,000mg) plus d-chiro-inositol (50mg) supplement powder twice daily.
Sponsors
Leads: University of Oklahoma

This content was sourced from clinicaltrials.gov